Wednesday Evening: |
Keynote Address: |
|
Sidney Brenner, Lynx Therapeutics (invited)
|
Thursday Morning: |
The Technology: Hardware/Genomics/Proteomics |
Afternoon: |
The Technology: Informatics
|
Friday Morning: |
Anti-cancer Drug Discovery |
|
Molecular Classification of Tumors |
Afternoon: |
Pharmacogenomics Molecular Pharmacology
|
Saturday Morning: |
Molecular Pathology |
Afternoon: |
Molecular Epidemiology
|
Sunday Morning: |
Keynote Address:
|
|
R. Klausner, Director, National Cancer Institute (invited) |
|
Summary of Meeting |
Scientific/Local Organizing Committee: Chair:
A. Nakeff
Henry Ford Health System,
One Ford Place,
Detroit, MI 48202
Tel: 313/874-4879
Fax: 313/874-6824
Email: anakeffl@hfhs.org
Detroit: F. Valeriote, C. Johnson, JAnagli, O. Boglar, M. Hughes, M Tainsky, P. Andrews, S. Hanash, L. Baker, R. Finley, D. van Dyke, D. Smith.
Industry: K. Sikora, C. Barker.
ISAC: J. Watson, J. Gray, D. Pinkel, D. Galbraith.
Industrial Exhibits: Genomic Solutions, BDIS/CLONTECH, Bio-Rad, Amersham Pharmacia Biotech, Affymetrix, Merck Genomics Research Lab., Hybridgenics, Genome Express, Borealis Biosciences, Proteome Systems, Phylos, Kinetek Pharmaceuticals, PE Biosystems, Bruker Daltonics, SmithKline Beecham Pharmaceuticals, Rosetta Inpharmatics, Hoechst, Parke Davis, Roche Diagnostics, SGI, Intergen, Beckman Instruments, Transduction Labs, IncyteGenomics, NIH, NCI.
Other Financial Contributors: Henry Ford Health System, Karmanos Cancer Center, U of Michigan, NCI, ISAC
Motown Microarray Symposium: Genomics/Proteomics in Cancer
International Society of Analytical Cytology’s
Third Samuel A. Latt Conference
May, 2001
Hotel St. Regis, Detroit, Michigan, USA
Scientific Program
THURSDAY
Morning: The Technology: Hardware/Genomics/Proteomics
- Chris Barker, Genomic Solutions
- Affymetrix
- BD/CLONTECH
- Stratagene
- Siobhan Pickett, Amersham Pharmacia Biotech
- Patrick Brown, Howard Hughes Medical Institute, Stanford
- PE Biosytems
- Bio-Rad Proteome Works System
- D. Muddiman, ESI-FTICR.MS
- R.S. Matson (Beckman), Automated DNA array processing
Afternoon: The Technology: Informatics
- Ann Holtz/Sejai Desai, CLONTECH, Atlas Select Human Tumor Array
- Mary E. Lopez, Genomic Solutions, proteomics
- Marc Wilkins, Proteome Systems
- Phylos, Proteomics
- Dan Pinkel, BAC DNA Arrays
- G. Riggins, SAGE, Serial Analysis of Gene Expression
- D. De Angelis, Fluorescence vs Radioactivity vs Phosphorescence
- Roland Somogyi, InCyte, From genes to predictions
- John Anagli, HFHS, Update on the Swiss Data Base
FRIDAY
Morning: Drug Discovery
- Nakeff HFHS, Molecular Pathways Utilized by Novel Anti-cancer Agents
- M. Vidal, Prospects for drug screening using the reverse two-hybrid system
J.E. Bailey, Lessons from metabolic engineering for functional genomics and drug discovery
- S. Huang, Gene expression profiling, genetics networks and cellular states: an integrating concept for tumorigenesis and drug discovery
- D. A. Jones, Genomics and the discovery of new drug targets
- S. Wilson, Orphan G-protein-coupled receptors: the next generation of drug targets?
- M. J. Marton, Drug target validation and identification of secondary drug target effects using DNA microarrays.
- S. Mullner, Proteomics - a new way for drug target discovery
- D.F. Veber, The new partnership of genomics and chemistry for accelerated drug development
Molecular Classification
- T.R. Golub, Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
- L. Baker, Molecular Classification of Sarcomas
- O. Boglar, HFHS, Molecular Classification of Brain Tumors
- L. Staudt, Lymphomas
- E. Gabrielson, Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles
- J. Pollock, Gene Amplification/Deletion in Tumors
- J. Green, Mammary/Prostate Tumor Development
Afternoon:
Pharmacogenomics
- W.E. Evans, Pharmacogenomics: Translating functional genomics into rational therapeutics
- S. Braxton (Incyte) Linking drug discovery with pharmacogenetics
Molecular Pharmacology
- J. N. Weinstein, An information-intensive approach to the molecular pharmacology of cancer
SATURDAY
Morning: Molecular Pathology
- P. Osin, Experimental pathology and breast cancer genetics: new technologies
Afternoon: Molecular Epidemiology
- C. Johnson, HFHS, Ethnicity, stage of detection of breast cancer and screening mammography in a health maintenance organization
SUNDAY
Morning: Keynote Address: Overview and Future Directions
- R. Klausner, Director, NCI, Cancer, Molecular Approaches to Cancer:
Progress and Programs (invited).
Summary:
- Mark Boguski, National Center for Biotechnical Information
Scientific/Local Organizing Committee:
Chair: A. Nakeff (Detroit/ISAC)
Henry Ford Health System
One Ford Place
Detroit, MI 48202
Tel: 313/874-4879
Fax: 313/874-6824
Email: anakeffl@hfbs.org
Detroit: F. Valeriote, J. Anagli, O. Boglar, M. Hughes, M Tainsky, P. Andrews, S. Hanash, L. Baker, R. Finley, D. van Dyke, D, Smith.
Industry: K. Sikora, C. Barker.
ISAC: J. Watson, J Gray, D. Pinkel, D. Galbraith
Industrial Exhibits:
Genomic Solutions, BDIS/CLONTECH, Bio-Rad, Amersham Pharmacia Biotech, Affymetrix, Merck Genomics Research Lab., Hybridgenics (Paris), Genome Express (Grenoble), Borealis Biosciences (Toronto), Proteome Systems (Sydney), Phylos (Lexington. MA), Kinetek Pharmaceuticals (Vancouver), PE Biosystems (Foster City, CA), Bruker Daltonics (Billerica, MA), SmithKline Beecham Pharmaceuticals, Rosetta Inpharmatics, Hoechst, Parke Davis, Roche Diagnostics, SGI, Intergen, Incyte, Beckman Instruments.
Other Financial Contributors: HFHS, Karmanos Cancer Center, U of Mich., NCI, ISAC